Severe hemolysis during primaquine radical cure of Plasmodium vivax malaria: two systematic reviews and individual patient data descriptive analyses

Primaquine (PQ) kills Plasmodium vivax hypnozoites but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. We conducted two systematic reviews. The first used data from clinical trials to determine the variety of definitions and frequency of hematological...

Full description

Bibliographic Details
Main Authors: Yilma, D, Groves, ES, Brito-Sousa, JD, Monteiro, WM, Chu, C, Thriemer, K, Commons, RJ, Lacerda, MVG, Price, RN, Douglas, NM
Format: Journal article
Language:English
Published: American Society of Tropical Medicine and Hygiene 2023
_version_ 1826311518299357184
author Yilma, D
Groves, ES
Brito-Sousa, JD
Monteiro, WM
Chu, C
Thriemer, K
Commons, RJ
Lacerda, MVG
Price, RN
Douglas, NM
author_facet Yilma, D
Groves, ES
Brito-Sousa, JD
Monteiro, WM
Chu, C
Thriemer, K
Commons, RJ
Lacerda, MVG
Price, RN
Douglas, NM
author_sort Yilma, D
collection OXFORD
description Primaquine (PQ) kills Plasmodium vivax hypnozoites but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. We conducted two systematic reviews. The first used data from clinical trials to determine the variety of definitions and frequency of hematological serious adverse events (SAEs) related to PQ treatment of vivax malaria. The second used data from prospective studies and case reports to describe the clinical presentation, management, and outcome of severe PQ-associated hemolysis necessitating hospitalization. In the first review, SAEs were reported in 70 of 249 clinical trials. There were 34 hematological SAEs among 9,824 patients with P. vivax malaria treated with PQ, nine of which necessitated hospitalization or blood transfusion. Criteria used to define SAEs were diverse. In the second review, 21 of 8,487 articles screened reported 163 patients hospitalized after PQ radical cure; 79.9% of whom (123 of 154) were prescribed PQ at ≥ 0.5 mg/kg/day. Overall, 101 patients were categorized as having probable or possible severe PQ-associated hemolysis, 96.8% of whom were G6PD deficient (< 30% activity). The first symptoms of hemolysis were reported primarily on day 2 or 3 (45.5%), and all patients were hospitalized within 7 days of PQ commencement. A total of 57.9% of patients (77 of 133) had blood transfusion. Seven patients (6.9%) with probable or possible hemolysis died. Even when G6PD testing is available, enhanced monitoring for hemolysis is warranted after PQ treatment. Clinical review within the first 5 days of treatment may facilitate early detection and management of hemolysis. More robust definitions of severe PQ-associated hemolysis are required.
first_indexed 2024-03-07T08:11:01Z
format Journal article
id oxford-uuid:60b2b3f8-b256-484c-88c6-d6e57cf47fbc
institution University of Oxford
language English
last_indexed 2024-03-07T08:11:01Z
publishDate 2023
publisher American Society of Tropical Medicine and Hygiene
record_format dspace
spelling oxford-uuid:60b2b3f8-b256-484c-88c6-d6e57cf47fbc2023-12-01T14:42:08ZSevere hemolysis during primaquine radical cure of Plasmodium vivax malaria: two systematic reviews and individual patient data descriptive analysesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:60b2b3f8-b256-484c-88c6-d6e57cf47fbcEnglishSymplectic ElementsAmerican Society of Tropical Medicine and Hygiene2023Yilma, DGroves, ESBrito-Sousa, JDMonteiro, WMChu, CThriemer, KCommons, RJLacerda, MVGPrice, RNDouglas, NMPrimaquine (PQ) kills Plasmodium vivax hypnozoites but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. We conducted two systematic reviews. The first used data from clinical trials to determine the variety of definitions and frequency of hematological serious adverse events (SAEs) related to PQ treatment of vivax malaria. The second used data from prospective studies and case reports to describe the clinical presentation, management, and outcome of severe PQ-associated hemolysis necessitating hospitalization. In the first review, SAEs were reported in 70 of 249 clinical trials. There were 34 hematological SAEs among 9,824 patients with P. vivax malaria treated with PQ, nine of which necessitated hospitalization or blood transfusion. Criteria used to define SAEs were diverse. In the second review, 21 of 8,487 articles screened reported 163 patients hospitalized after PQ radical cure; 79.9% of whom (123 of 154) were prescribed PQ at ≥ 0.5 mg/kg/day. Overall, 101 patients were categorized as having probable or possible severe PQ-associated hemolysis, 96.8% of whom were G6PD deficient (< 30% activity). The first symptoms of hemolysis were reported primarily on day 2 or 3 (45.5%), and all patients were hospitalized within 7 days of PQ commencement. A total of 57.9% of patients (77 of 133) had blood transfusion. Seven patients (6.9%) with probable or possible hemolysis died. Even when G6PD testing is available, enhanced monitoring for hemolysis is warranted after PQ treatment. Clinical review within the first 5 days of treatment may facilitate early detection and management of hemolysis. More robust definitions of severe PQ-associated hemolysis are required.
spellingShingle Yilma, D
Groves, ES
Brito-Sousa, JD
Monteiro, WM
Chu, C
Thriemer, K
Commons, RJ
Lacerda, MVG
Price, RN
Douglas, NM
Severe hemolysis during primaquine radical cure of Plasmodium vivax malaria: two systematic reviews and individual patient data descriptive analyses
title Severe hemolysis during primaquine radical cure of Plasmodium vivax malaria: two systematic reviews and individual patient data descriptive analyses
title_full Severe hemolysis during primaquine radical cure of Plasmodium vivax malaria: two systematic reviews and individual patient data descriptive analyses
title_fullStr Severe hemolysis during primaquine radical cure of Plasmodium vivax malaria: two systematic reviews and individual patient data descriptive analyses
title_full_unstemmed Severe hemolysis during primaquine radical cure of Plasmodium vivax malaria: two systematic reviews and individual patient data descriptive analyses
title_short Severe hemolysis during primaquine radical cure of Plasmodium vivax malaria: two systematic reviews and individual patient data descriptive analyses
title_sort severe hemolysis during primaquine radical cure of plasmodium vivax malaria two systematic reviews and individual patient data descriptive analyses
work_keys_str_mv AT yilmad severehemolysisduringprimaquineradicalcureofplasmodiumvivaxmalariatwosystematicreviewsandindividualpatientdatadescriptiveanalyses
AT groveses severehemolysisduringprimaquineradicalcureofplasmodiumvivaxmalariatwosystematicreviewsandindividualpatientdatadescriptiveanalyses
AT britosousajd severehemolysisduringprimaquineradicalcureofplasmodiumvivaxmalariatwosystematicreviewsandindividualpatientdatadescriptiveanalyses
AT monteirowm severehemolysisduringprimaquineradicalcureofplasmodiumvivaxmalariatwosystematicreviewsandindividualpatientdatadescriptiveanalyses
AT chuc severehemolysisduringprimaquineradicalcureofplasmodiumvivaxmalariatwosystematicreviewsandindividualpatientdatadescriptiveanalyses
AT thriemerk severehemolysisduringprimaquineradicalcureofplasmodiumvivaxmalariatwosystematicreviewsandindividualpatientdatadescriptiveanalyses
AT commonsrj severehemolysisduringprimaquineradicalcureofplasmodiumvivaxmalariatwosystematicreviewsandindividualpatientdatadescriptiveanalyses
AT lacerdamvg severehemolysisduringprimaquineradicalcureofplasmodiumvivaxmalariatwosystematicreviewsandindividualpatientdatadescriptiveanalyses
AT pricern severehemolysisduringprimaquineradicalcureofplasmodiumvivaxmalariatwosystematicreviewsandindividualpatientdatadescriptiveanalyses
AT douglasnm severehemolysisduringprimaquineradicalcureofplasmodiumvivaxmalariatwosystematicreviewsandindividualpatientdatadescriptiveanalyses